| Not Yet Recruiting | Dapagliflozin for Anemia in Lower-Risk Myelodysplastic Syndromes NCT07516847 | Seug yun Yoon, MD | Phase 2 |
| Not Yet Recruiting | Asia Myelodysplastic Syndrome (MDS) Registry NCT07355478 | Bristol-Myers Squibb | — |
| Not Yet Recruiting | Pre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT NCT07319793 | Peking University People's Hospital | N/A |
| Recruiting | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Mal NCT07238712 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies NCT06656494 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 |
| Recruiting | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Na NCT06465953 | Institut de Recherches Internationales Servier | Phase 3 |
| Withdrawn | A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myel NCT06581055 | Bristol-Myers Squibb | — |
| Active Not Recruiting | A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept NCT06971185 | Bristol-Myers Squibb | — |
| Recruiting | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial NCT06765876 | Institute of Hematology and Blood Transfusion, Czech Republic | EARLY_Phase 1 |
| Recruiting | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral NCT06398457 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndr NCT06764511 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Recruiting | Cord Blood Transplant in Adults With Blood Cancers NCT05884333 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus NCT05709093 | TJ Biopharma Co., Ltd. | Phase 3 |
| Recruiting | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphod NCT05092451 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes NCT04997811 | Prof. Janet Dunn | Phase 2 |
| Recruiting | Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant NCT04898790 | University of Nebraska | N/A |
| Withdrawn | A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic S NCT04985656 | Takeda | Phase 2 |
| Recruiting | Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With H NCT06886425 | Assistance Publique Hopitaux De Marseille | N/A |
| Active Not Recruiting | A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Pr NCT04872595 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Pharmacokinetics, Tolerability and Safety of NEX-18a NCT05048498 | Nanexa AB | Phase 1 |
| Withdrawn | Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) NCT04395092 | Kiadis Pharma | Phase 2 |
| Recruiting | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML NCT04275518 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy o NCT04202003 | TJ Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Cli NCT04064060 | Celgene | Phase 3 |
| Active Not Recruiting | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in NCT03849651 | St. Jude Children's Research Hospital | Phase 2 |
| Terminated | A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS NCT03593915 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Terminated | Panobinostat Maintenance After HSCT fo High-risk AML and MDS NCT04326764 | Goethe University | Phase 3 |
| Unknown | Collection of Samples From Patients With MDS NCT03072498 | PersImmune, Inc | — |
| Completed | A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refracto NCT02966782 | AbbVie | Phase 1 |
| Active Not Recruiting | A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk NCT02942290 | AbbVie | Phase 1 |
| Completed | The National Myelodysplastic Syndromes (MDS) Study NCT02775383 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Unknown | A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS) NCT02779569 | The First Affiliated Hospital with Nanjing Medical University | N/A |
| Completed | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients NCT02550535 | Cell Medica Ltd | Phase 1 / Phase 2 |
| Completed | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies NCT02333058 | medac GmbH | Phase 2 |
| Unknown | Red Blood Cell Transfusion Thresholds and QOL in MDS NCT02099669 | Sunnybrook Health Sciences Centre | N/A |
| Completed | Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients Wit NCT01995578 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT NCT01885897 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Completed | Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) NCT01736683 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS NCT01613976 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell NCT01660607 | Stanford University | Phase 1 / Phase 2 |
| Terminated | Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS NCT01442714 | Stanford University | Phase 2 |
| Completed | The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study NCT02390414 | Dana-Farber Cancer Institute | — |
| Completed | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodyspl NCT01392989 | Everett Meyer | Phase 2 |
| Completed | A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), Wi NCT01488565 | Peter MacCallum Cancer Centre, Australia | Phase 2 |
| Terminated | Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia NCT01034592 | Jason Robert Gotlib | Phase 1 |
| Completed | B-Receptor Signaling in Cardiomyopathy NCT01135849 | Daniel Bernstein | — |
| Completed | Screening and Genetic Monitoring of Patients With Myelodysplastic Syndromes (MDS) Under Different Treatment Mo NCT01355913 | Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH | — |
| Unknown | A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes NCT00600860 | Radboud University Medical Center | — |
| Terminated | LBH589 in Refractory Myelodysplastic Syndromes (MDS) NCT00594230 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, NCT00528983 | Celgene | Phase 1 |
| Completed | A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS) NCT00230321 | Peter L Greenberg | Phase 1 / Phase 2 |
| Completed | Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders NCT00186576 | Stanford University | N/A |
| Completed | Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies NCT00186342 | Stanford University | N/A |